This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2019 Aug;156(2):209-210.

doi: 10.1016/j.chest.2019.03.028.

Rebuttal From Dr Ley

Brett Ley¹

Affiliations

Affiliation

¹ Department of Pulmonary and Critical Care Medicine, Kaiser Permanente San Francisco, San Francisco, CA; Department of Medicine, University of California San Francisco, CA. Electronic address: brett.ley@ucsf.edu.

PMID: 31395258
DOI: 10.1016/j.chest.2019.03.028

Editorial

Rebuttal From Dr Ley

Brett Ley. Chest. 2019 Aug.

. 2019 Aug;156(2):209-210.

doi: 10.1016/j.chest.2019.03.028.

Author

Brett Ley¹

Affiliation

¹ Department of Pulmonary and Critical Care Medicine, Kaiser Permanente San Francisco, San Francisco, CA; Department of Medicine, University of California San Francisco, CA. Electronic address: brett.ley@ucsf.edu.

PMID: 31395258
DOI: 10.1016/j.chest.2019.03.028

No abstract available

PubMed Disclaimer

Comment on

POINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? Yes.
Prasse A. Prasse A. Chest. 2019 Aug;156(2):203-205. doi: 10.1016/j.chest.2019.03.026. Chest. 2019. PMID: 31395255 No abstract available.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey